Document Detail

TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications.
MedLine Citation:
PMID:  22736025     Owner:  NLM     Status:  Publisher    
PURPOSE: Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) represents a central point of convergence for the signal transduction by the TNFR and the IL-lR/TLR superfamilies. We conducted this retrospective clinical study focusing on TRAF6 expression associated with overall survival and chemotherapeutical sensitivity in a large population with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 324 patients with stage III and IV NSCLC were retrospectively enrolled. Immunohistochemistry was performed to evaluate the expression of TRAF6, apoptosis-related proteins Bcl-2, Bax, Fas, and FasL, as well as the density of CD8(+) and FOXP3(+) tumor infiltrating lymphocytes (TILs) in tumor microenvironment. RESULTS: A total of 193 carcinomas (59.6 %) were identified as high expression of TRAF6. TRAF6 expression was not significantly related with histology and clinic stage. No obvious correlation of TRAF6 expression with apoptosis-related protein and TILs density was identified. TRAF6 status was correlated inversely with response to chemotherapy in overall patients (response rates 24.9 and 32.8 %, for patients with high-TRAF6 and low-TRAF6 tumors, respectively, P = 0.039). However, multivariate logistic regression analysis could not identify TRAF6 status as an independent predictor for the response to chemotherapy in overall cohort (95 % CI: 0.91-3.32, P = 0.065). The overall survival was not significantly associated with TRAF6 expression (P = 0.616). CONCLUSIONS: Our results provide new insight for the biological properties and clinical relevance of the TRAF6 in NSCLC. TRAF6 is a promise target for therapeutic strategies against cancer.
Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou
Related Documents :
16518065 - Immunohistochemical evaluation of hormone receptor status for predicting response to en...
18457865 - Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high...
16894565 - Molecular determinants of irinotecan efficacy.
22806575 - Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic rev...
22292735 - Prognostic value of bcl-2 and bax tumor cell expression in patients with non muscle-inv...
4039625 - Doxorubicin plus cisplatin in the treatment of apudomas.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-27
Journal Detail:
Title:  Journal of cancer research and clinical oncology     Volume:  -     ISSN:  1432-1335     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902060     Medline TA:  J Cancer Res Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Pulmonary and Critical Care, Department of Internal Medicine, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe street, Guangzhou, 510630, China,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppressi...
Next Document:  HIF-1? induced by ?-elemene protects human osteosarcoma cells from undergoing apoptosis.